Patzold U, Pocklington P
J Neurol. 1980;223(2):97-117. doi: 10.1007/BF00313173.
The results of a prospective, long-term controlled study on the treatment of multiple sclerosis with azathioprine are reported. The effect of a daily 2 mg/kg body weight dosage on 56 randomly chosen patients with multiple sclerosis is compared with a non-treated control group of 51 randomly selected multiple sclerosis patients. The azathioprine therapy was continued in all cases for more than one year, on average for 732 days. To assess the effect of therapy, the course of the disease was followed by regular examinations evaluating the severity of the disease by use of an objective weighting-scale covering the whole range of neurological signs. The individual course of the disease within the observation period was determined by means of regression analysis. On average, the disease deteriorated less rapidly for those undergoing azathioprine therapy, this being most marked for patients who had had the disease for less than two years. For those who had been affected for longer, no significant differences in the progression of the disease could be detected. The annual relapse rate was the same for both categories.
报告了一项关于硫唑嘌呤治疗多发性硬化症的前瞻性长期对照研究结果。将每日2毫克/千克体重剂量对56例随机选择的多发性硬化症患者的疗效与51例随机选择的未治疗的多发性硬化症患者对照组进行比较。所有病例中硫唑嘌呤治疗均持续一年以上，平均732天。为评估治疗效果，通过定期检查跟踪疾病进程，使用涵盖整个神经体征范围的客观加权量表评估疾病严重程度。通过回归分析确定观察期内疾病的个体进程。平均而言，接受硫唑嘌呤治疗的患者疾病恶化速度较慢，对于患病不到两年的患者最为明显。对于患病时间较长的患者，未检测到疾病进展有显著差异。两类患者的年复发率相同。
